Compare Crispr Therapeutics AG (CRSP) vs Futu Holdings Ltd (FUTU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Futu Holdings Ltd — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Futu Holdings Ltd trades at $113.71 (market cap $15.25B). The key difference: Futu Holdings Ltd is far larger — about 3.1× Crispr Therapeutics AG's market cap, and Futu Holdings Ltd pays a 2.39% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Futu Holdings Ltd for 34 Days on average.
| CRSP | FUTU | |
|---|---|---|
Market Cap | $4.88B | $15.25B |
Volume | 2,861,747 | 812,567 |
Sector | Health | Financials |
52-Week High | $73.97 | $199.04 |
52-Week Low | $44.34 | $89.76 |
Typical Hold Time | 77 Days | 34 Days |
Enterprise Value | $3.30B | $15.59B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% amid bearish technical signals. The company shows negative profitability with -$581.60M net income and -4,101.26% net margin for 2025, though Q2 2026 EPS beat expectations. Positive analyst sentiment persists with 57.9% buy ratings and $67.83 consensus target. Recent clinical data presentations and CASGEVY commercial progress provide catalysts.
The stock faces fundamental challenges with persistent losses and negative cash flow from operations, but maintains Wall Street support for its gene-editing pipeline. Key risks include clinical trial outcomes and cash burn, while potential upside hinges on successful drug commercialization and upcoming data readouts through 2026.
Futu Holdings trades at $108.76, down 0.84% today, with a bearish technical signal despite strong fundamentals. The company reported robust Q2 2026 earnings of $3.33 EPS, beating estimates by 12%, and maintains impressive profitability with 42.92% net income margin and 30.8% ROE. Recent news highlights Moomoo's expansion initiatives and ongoing securities class action lawsuits with August 2026 deadlines.
Wall Street analysts project 33.7% upside potential with 58% buy ratings, but technical indicators and legal risks warrant caution. The stock presents value at 10.86 P/E ratio with strong cash flow generation, though bearish momentum and regulatory scrutiny may pressure near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →
